Key result
The cytohesin inhibitor secinH3 reduced prostate smooth muscle contractions induced by various agonists and electric field stimulation, and inhibited the small monomeric GTPase ARF6.
Inhibition of cytohesin GEFs by secinH3 reduces human prostate smooth muscle contraction via an ARF6 pathway, suggesting a potential new target for male lower urinary tract symptoms.
SecinH3 reduces prostate contractions via ARF6; hypothesis-generating for cytohesin-ARF6 targeting in LUTS, needs clinical validation.
Prostate smooth muscle contraction is critical for etiology and treatment of male lower urinary tract symptoms (LUTS) and is promoted by small monomeric GTPases (RhoA and Rac). GTPases may be activated by guanosine nucleotide exchange factors (GEFs). GEFs of the cytohesin family may indirectly activate Rac, or ADP ribosylation factor (ARF) GTPases directly. Here we investigated the expression of cytohesin family GEFs and effects of the cytohesin inhibitor Sec7 inhibitor H3 (secinH3) on smooth muscle contraction and GTPase activities in human prostate tissues. Of all four cytohesin isoforms, cytohesin-1 and -2 showed the highest expression in real-time PCR. Western blot and fluorescence staining suggested that cytohesin-2 may be the predominant isoform in prostate smooth muscle cells. Contractions induced by norepinephrine, the α1-adrenoceptor agonist phenylephrine, the thromboxane A2 analog U-46619 , and endothelin-1 and -3, as well as neurogenic contractions induced by electric field stimulation (EFS), were reduced by secinH3 (30 µM). Inhibition of EFS-induced contractions appeared to have efficacy similar to that of inhibition by the α1-adrenoceptor antagonist tamsulosin (300 nM). Combined application of secinH3 plus tamsulosin caused larger inhibition of EFS-induced contractions than tamsulosin alone. Pull-down assays demonstrated inhibition of the small monomeric GTPase ARF6 by secinH3, but no inhibition of RhoA or Rac1. In conclusion, we suggest that a cytohesin-ARF6 pathway takes part in smooth muscle contraction. This may open attractive new possibilities in medical treatment of male LUTS.
No takes yet. Share an insight, caveat, or question.
Herlemann et al. (2017) studied Male lower urinary tract symptoms (LUTS). secinH3 vs. tamsulosin or control was evaluated on Smooth muscle contraction and GTPase activities. The cytohesin inhibitor secinH3 reduced prostate smooth muscle contractions induced by various agonists and electric field stimulation, and inhibited the small monomeric GTPase ARF6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: